Large Study of PrEP Use in Clinical Practice Shows No New HIV Infections
September 1, 2015 - SAN FRANCISCO - In one of the first and largest published
evaluations of the use of preexposure prophylaxis (known as PrEP) to prevent HIV infection in
a clinical practice setting, researchers at Kaiser Permanente found no new HIV infections
among patients during more than 2.5 years of observation. The study was published today
in the journal Clinical Infectious Diseases.
“Our study is the first to extend the understanding of the use of PrEP in a real-world setting and suggests that
the treatment may prevent new HIV infections even in a high-risk setting,” reported lead
author Jonathan Volk, MD, MPH, physician
and epidemiologist at Kaiser Permanente San Francisco Medical Center.
“Until now, evidence supporting the efficacy of PrEP to prevent HIV infection had come from clinical
trials and a demonstration project.”
In 2012, the U.S. Food and Drug Administration approved
a fixed-dose treatment of the antiviral drugs emtricitabine and tenofovir for daily use in combination
with safer sex practices as a way of preventing HIV infection in people who do not have HIV, but
are at high risk of getting it. When someone is exposed to HIV through sexual activity or
injection drug use, these medications in a single pill, known commercially as Truvada,
can keep an infection from becoming permanent.
Over the 32-month observation period at Kaiser Permanente San Francisco Medical Center, there were
1,045 referrals for PrEP and 657 people who began the PrEP regimen. The average length of use
during the study period was 7.2 months, resulting in 388 person-years of observation of
PrEP use. The average age of PrEP users was 37, and 99 percent were men who have
sex with men. Compared with people who did not use the PrEP protocol, users were
more likely to report multiple sex partners, and were not more likely to report
having an HIV-infected sexual partner.
Of 143 patients who were asked about behavior change after six months of PrEP use, the number of sexual
partners was unchanged in 74 percent, decreased in 15 percent, and increased in 11 percent. Condom use
was unchanged in 56 percent, decreased in 41 percent, and increased in 3 percent.
At six months after initiation, 30 percent of PrEP users had been diagnosed with at least one sexually
transmitted infection, or STI. At 12 months, 50 percent of PrEP users had been diagnosed with any
STI; 33 percent had a rectal STI, 33 percent had chlamydia, 28 percent had gonorrhea, and 5.5
percent had syphilis.
“Without a control group, we don't know if these STI rates were higher than what we would have seen
without PrEP,” said co-author Julia Marcus, PhD, MPH, postdoctoral
fellow at the Kaiser Permanente Division of Research. “Ongoing
screening and treatments for STIs, including hepatitis C, are an essential component of a PrEP treatment
According to senior author Bradley Hare, MD, director
of HIV Care and Prevention at Kaiser Permanente San Francisco, people on a PrEP regimen should be tested frequently for STIs and monitored closely for HIV infection, as well as for side effects of Truvada, including changes in kidney function.
While researchers observed that demand for PrEP is growing among men who have sexual encounters
with men, they also underscored the need for outreach to others at risk for HIV, including
transgender women, heterosexual men and women, and people using injection drugs.
Other authors of the study include Tony Phengrasamy, PharmD, Derek Blechinger, MD, Dong Phuong Nguyen,
PharmD, and Stephen Follansbee, MD, of the Kaiser Permanente San Francisco Medical Center Department
of Adult and Family Medicine.
About the Kaiser Permanente Division of Research
The Kaiser Permanente Division of Research conducts, publishes and disseminates epidemiologic and health
services research to improve the health and medical care of Kaiser Permanente members and society
at large. It seeks to understand the determinants of illness and well-being, and to improve the
quality and cost-effectiveness of health care. Currently, DOR's 500-plus staff is working on
more than 400 epidemiological and health services research projects. For more information,
visit www.dor.kaiser.org or follow us @KPDOR.
About Kaiser Permanente
Kaiser Permanente is committed to helping shape the future of health care. We are recognized as
one of America's leading health care providers and not-for-profit health plans. Founded in
1945, Kaiser Permanente has a mission to provide high-quality, affordable health care
services and to improve the health of our members and the communities we serve. We
currently serve more than 10 million members in eight states and the District
of Columbia. Care for members and patients is focused on their total health
and guided by their personal physicians, specialists and team of
caregivers. Our expert and caring medical teams are empowered
and supported by industry-leading technology advances and
tools for health promotion, disease prevention, state-of-the-art care delivery and world-class
chronic disease management. Kaiser Permanente is dedicated to care innovations, clinical
research, health education and the support of community health. For more information,
go to: kp.org/share.
SOURCE: Kaiser Permanente
"Reproduced with permission - Kaiser Permanente"
For more HIV and AIDS News visit...
Positively Positive - Living with HIV/AIDS: